Water → 3-(Chloromethylene)-7-[4-(2-methyl-1,3-dioxolan-2-yl)-1-butenyl]-2,3-dihydro-1-benzoxepin

HRID 1791057Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1791057
C([Li])CCC.[I-].[CH3:7][C:8]1([CH2:13][CH2:14][CH2:15][P+](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[O:12][CH2:11][CH2:10][O:9]1.[Cl:35][CH:36]=[C:37]1[CH:43]=[CH:42][C:41]2[CH:44]=[C:45]([CH:48]=O)[CH:46]=[CH:47][C:40]=2[O:39][CH2:38]1.O>O1CCCC1.ClCCl>[Cl:35][CH:36]=[C:37]1[CH:43]=[CH:42][C:41]2[CH:44]=[C:45]([CH:48]=[CH:15][CH2:14][CH2:13][C:8]3([CH3:7])[O:9][CH2:10][CH2:11][O:12]3)[CH:46]=[CH:47][C:40]=2[O:39][CH2:38]1

Komponenten

7

Edukt 4

HCID 962WaterHCID 10029588Phosphonium, [3-(2-methyl-1,3-dioxolan-2-yl)propyl]triphenyl-, iodideHCID 74027557HCID 74027557, VerbindungHCID 178418339Butyllithium

Produkt 1

HCID 696664473-(Chloromethylene)-7-[4-(2-methyl-1,3-dioxolan-2-yl)-1-butenyl]-2,3-dihydro-1-benzoxepinAusbeute 71 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 6344DichloromethaneLösungsmittelHCID 8028TetrahydrofuranLösungsmittel2×

Reaktionsbedingungen

Temperatur
0 °C

Versuchsvorschrift

0.206 ml (0.41 mmol) of a 1.9M n-butyllithium solution is added dropwise to 207 mg (0.435 mmol) of [3-(2-methyl-1,3-dioxolan-2-yl)propyl](triphenyl)phosphonium iodide in suspension in 3.2 ml of tetrahydrofuran cooled to 0° C. The medium is stirred for one hour and then the ylide is added at 0° C., via a hollow tube, to 48 mg (0.22 mmol) of 3-(chloromethylene)-2,3-dihydro-1-benzoxepin-7-carbaldehyde, prepared according to example 72, in solution in 3.6 ml of tetrahydrofuran. The medium is stirred at ambient temperature for 25 minutes and then water and dichloromethane are added. The phases are separated and the aqueous phase is extracted with dichloromethane. The combined organic phases are then washed with brine, are then dried and are then finally concentrated under vacuum. The crude reaction product is purified by chromatography on silica gel (ethyl acetate/heptane 10/90) to give 47 mg (71%) of 3-(chloromethylene)-7-[4-(2-methyl-1,3-dioxolan-2-yl)-1-butenyl]-2,3-dihydro-1-benzoxepin in the form of a mixture of four diastereoisomers in a Z/E (60/40) ratio for the unsaturated chain and a Z/E ratio (85/15) for the chloromethylene functional group; 1H NMR (300 MHz, CDCl3) ZZ isomer: 1.32 (s, 3H), 1.81 (m, 2H), 2.44 (m, 2H), 3.9 (m, 4H), 4.86 (s, 2H), 5.63 (m, 1H), 6.31 (m, 4H), 6.96 (m, 3H).

Aufarbeitung

  1. customprepared
  2. stirringThe medium is stirred at ambient temperature for 25 minutes
  3. customThe phases are separated
  4. extractionthe aqueous phase is extracted with dichloromethane
  5. washThe combined organic phases are then washed with brine
  6. customare then dried
  7. concentrationare then finally concentrated under vacuum
  8. customThe crude reaction product
  9. customis purified by chromatography on silica gel (ethyl acetate/heptane 10/90)

Quellen und Nachweise

ORD-Eintrag
ord-c0e13ba0b93e45088f5ce0a2dc8c4dcf
Quelldatensatz
uspto-grants-2006_07
Patentnummer
US07071340B2

Notizen zur Reaktion

Wird geladen…